Postdoktor inom mRNA-baserad CAR T-cellsterapi

Marcus Buggert’s group at the Centre for Infectious Medicine develops mRNA-based, CD19-directed CAR T cells for chronic lymphocytic leukaemia. The project uses electroporation and targeted lipid nanoparticles to generate transient CAR expression and examines how disease stage, treatment and T-cell differentiation affect killing of malignant B cells. Work combines primary human cells and patient samples, functional co-cultures, high-parameter flow cytometry and live-cell imaging to study killing kinetics, serial killing and repeated mRNA delivery.

Phenotypic, transcriptional and epigenetic analyses will identify mechanisms limiting cytotoxicity and routes to improve receptor availability and function. This full-time postdoctoral appointment is based in Flemingsberg; applications through Varbi close on 6 October 2026.

PhD in immunology, biomedicine, cell biology, molecular biology or a related field by the employment decision. Documented experimental human immunology, T-cell biology, flow cytometry and functional cell assays, plus excellent English. CAR T-cell, mRNA-delivery and haematological-cancer experience are valuable. Submit a doctoral-degree certificate, CV, publications and a one-page current-work summary in English or Swedish.